Stockhub

Xenetic Biosciences, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

21 August 2022

14 August 2022

5 August 2022

  • curprev 08:5408:54, 5 August 2022‎ Paris talk contribs‎ 839 bytes +839‎ Created page with "Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the discovery, research, and development of biologic drugs and oncology therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment o..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Xenetic_Biosciences,_Inc.’